TNF-α neutralizing agent;Les inhibiteurs du TNFα

Revue du Praticien

Volumn 53, Issue 18, 2003, Pages 1989-1990

  Fain, Olivier ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; DOSE RESPONSE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; SARCOIDOSIS; SHORT SURVEY; SJOEGREN SYNDROME; TREATMENT PLANNING; UVEITIS; VASCULAR DISEASE; ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CHILD; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; SAPHO SYNDROME; TIME; VASCULITIS;

ACQUIRED HYPEROSTOSIS SYNDROME; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; BEHCET SYNDROME; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTICENTER STUDIES; PLACEBOS; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; SJOGREN'S SYNDROME; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 0348143000     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
2. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
3. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
4. Salvarani C, Cantini F, Olivieri I et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49: 541-5.
5. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003; 48: 829-35.
6. Lovell DJ, Giannini EH, Reiff A et al. Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-26.
7. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacity of the anti-TNFalpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients, Rheumatology 2002; 41: 1126-32.
8. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002; 41: 1303-7.
9. Rozenbaum M, Rosner I, Portnoy E. Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002; 61: 283-4.
10. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001; 358: 1644.
11. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-8.
12. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30: 1864-7.
13. Utz JP, Limper AH, Kalra S et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85.
14. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001; 44: 2371-5.
15. Wallace DJ. The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious. J Rheumatol 2003; 30: 1897-9.